TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Lyell Immunopharma, Inc.
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma presented clinical trial data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, highlighting promising response rates and safety profile at the 67th ASH Annual Meeting.

Insights
LYEL   positive

Company presented promising clinical trial data with high response rates, received FDA designations (RMAT and Fast Track), and is advancing development of a novel CAR T-cell therapy with potential differentiated benefits